natgillin/translations-raw huggingface dataset:
How is Jakavi used? 
Kako se zdravilo Jakavi uporablja?
Date of first authorisation: 21 April 2008 Date of latest renewal: 20 December 2012 
Datum prve odobritve: 21 april 2008 Datum zadnjega podaljšanja: 20 december 2012
Table 2 summarises the primary efficacy endpoint results: 
V tabeli 2 so povzeti izidi primarnih opazovanih dogodkov učinkovitosti:
Not everyone gets flares, but you could get a flare-up even if you are taking ADENURIC, and especially during the first weeks or months of treatment. 
Do izbruha ne pride pri vseh ljudeh, vendar se lahko pojavi tudi, če jemljete zdravilo ADENURIC, še zlasti v prvih tednih ali mesecih zdravljenja.
Your doctor might decide to permanently stop treatment with ADENURIC. 
Vaš zdravnik se lahko odloči, da za stalno prekine zdravljenje z zdravilom Adenuric.
BL 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52 
BL 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52 Teden
Over time, gout flares will occur less often and be less painful if you keep taking ADENURIC every day. 
Čez čas se bodo izbruhi protina pojavljali manj pogosto in bodo manj boleči, če boste nadaljevali z jemanjem zdravila ADENURIC vsak dan.
ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICITONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
The efficacy and safety of ADENURIC in the prevention and treatment of Tumor Lysis Syndrome was evaluated in the FLORENCE (FLO-01) study. 
Učinkovitost in varnost zdravila ADENURIC pri preventivi in zdravljenju sindroma tumorske lize sta bili ocenjeni v študiji FLORENCE (FLO-01).
The requirements for submission of periodic safety updated reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
• Redna posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
• If you are allergic to febuxostat or any of the other ingredients of this medicine (listed in section 
• če ste alergični na febuksostat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Should you experience allergic reactions to ADENURIC, stop taking this medicine (see also section 4). 
Če se med zdravljenjem z zdravilom ADENURIC pojavijo alergijske reakcije, prenehajte jemati zdravilo (glejte tudi poglavje 4).
Plasma protein binding of the active metabolites ranges from about 82% to 91%. 
Delež vezave aktivnih presnovkov na plazemske beljakovine je približno 82 % do 91 %.
14 film-coated tablets 28 film-coated tablets 42 film-coated tablets 56 film-coated tablets 84 film-coated tablets 98 film-coated tablets 
14 filmsko obloženih tablet 28 filmsko obloženih tablet 42 filmsko obloženih tablet 56 filmsko obloženih tablet 84 filmsko obloženih tablet 98 filmsko obloženih tablet
In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department. 
V primeru nenamerno vzetega prevelikega odmerka se o tem, kaj morate storiti, posvetujte s svojim zdravnikom ali pojdite v najbližji urgentni oddelek za nezgode in nujne primere.
If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine. 
Če se pri vas razvije izpuščaj ali ti kožni simptomi, se nemudoma posvetujte z zdravnikom in mu povejte, da jemljete to zdravilo.
Febuxostat tablets contain lactose. 
Tablete febuksostata vsebujejo laktozo.
About 69 % of patients required no treatment change to achieve a final stable treatment. 
Približno 69 % zdravljenih bolnikov je doseglo končno stabilno stanje brez potrebne spremembe režima zdravljenja.
It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with ADENURIC and your doctor may wish to consider necessary measures: 
Zlasti pomembno je, da zdravnika ali farmacevta obvestite, če jemljete zdravila, ki vsebujejo katero od naslednjih učinkovin, da bo vaš zdravnik ocenil, ali so potrebni ustrezni ukrepi, saj lahko pride do medsebojnega delovanja z zdravilom ADENURIC:
The effect of ADENURIC on human fertility is unknown. 
Učinek zdravila ADENURIC na plodnost pri človeku ni znan.
The endpoints (primary and secondary) were analysed according to the intention-to-treat (ITT) analysis including all subjects who were randomized and received at least one dose of double-blind study medication. 
Opazovane dogodke (primarne in sekundarne) so preučili v skladu z analizo vključenih bolnikov (ITT - Intention-To-Treat), ki je vključevala vse bolnike, ki so bili randomizirani in so prejeli vsaj en odmerek dvojno slepega zdravila v preskušanju.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see also section 4.8). 
Preobčutljivost na zdravilno učinkovino ali katerokoli pomožno snov navedeno v poglavju 6.1 (glejte tudi poglavje 4.8).
What ADENURIC is and what it is used for 
Kaj je zdravilo ADENURIC in za kaj ga uporabljamo
Furthermore, the mean serum uric acid level was significantly lower with ADENURIC since the first 24 hours of treatment and at any following time point. 
Tudi srednja serumska vrednost sečne kisline je bila značilno manjša pri uporabi zdravila ADENURIC od prvih 24 ur zdravljenja naprej in v vseh nadaljnih časovnih točkah.
If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with ADENURIC. 
Če imate trenutno izbruh protina (nenadni občutek hude bolečine, napetosti, pordelosti, toplote in oteklosti sklepa), počakajte, da izbruh protina mine, preden začnete zdravljenje z zdravilom ADENURIC.
Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1). 
Preverjanje delovanja jeter se priporoča pred začetkom zdravljenja s febuksostatom in nato periodično v skladu s klinično presojo (glejte poglavje
ADENURIC is for adults. 
Zdravilo ADENURIC je za odrasle.
ADENURIC film-coated tablets are pale yellow to yellow in colour and capsule shaped. 
Filmsko obložene tablete ADENURIC so svetlorumene do rumene barve v obliki kapsul.
Following multiple oral doses of ADENURIC, the Cmax and AUC were 24% and 12% higher in females than in males, respectively. 
Po večkratnih peroralnih odmerkih zdravila ADENURIC sta bili Cmax za 24 % in AUC za 12 % večji pri ženskah kot pri moških.
• severe swelling of the deeper layers of the skin, especially around the lips, eyes, genitals, hands, feet or tongue, with possible sudden difficult breathing 
• Hudo otekanje spodnjih slojev kože, predvsem v področju ustnic, oči, spolovil, dlani, stopal ali jezika, z možno nenadno otežitvijo dihanja.
• If you have or have had renal disease and/or serious allergic reaction to Allopurinol (a medication used for the treatment of Gout) 
• če imate ali ste imeli bolezen ledvic in/ali resne alergijske reakcije na alopurinol (zdravilo za zdravljenje protina),
Overall, the FLORENCE trial did not highlight any particular safety concern in addition to the previous experience with ADENURIC in gout, with the exception of the following three adverse reactions (listed above in table 1). 
Na splošno v FLORENCE študiji, glede na prejšnje izkušnje z zdravljenjem protina z zdravilom ADENURIC, niso izpostavili nobenih posebnih varnostnih težav, z izjemo treh naslednjih neželenih učinkov (navedenih v Tabeli 1 zgoraj):
BL=baseline SEM=standard error of the mean 
BL=izhodišče SEM=standardna napaka srednje vrednosti
Incidence of overall treatment-emergent signs and symptoms and adverse drug reactions was 67.6% vs 64.7% and 6.4% vs 6.4% with ADENURIC and allopurinol respectively. 
Incidenca z zdravljenjem povezanih znakov in simptomov ter neželenih učinkov je bila 67,6 % proti 64,7 % in 6,4 % za zdravilo ADENURIC v primerjavi proti 6,4 % pri alopurinolu.
The safety and the efficacy of ADENURIC in children aged below the age of 18 years have not been established. 
Varnost in učinkovitost zdravila ADENURIC pri otrocih, starih do 18 let še nista bili dokazani.
If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be restarted on ADENURIC at any time. 
Če se je pri vas po jemanju febuksostata razvil Stevens-Johnsonov sindrom, ne smete nikoli ponovno začeti jemati zdravila ADENURIC.
Start taking ADENURIC two days before chemotherapy and continue its use according to your doctor's advice. 
Začnite jemati zdravilo ADENURIC dva dni pred kemoterapijo in z jemanjem nadaljujte v skladu z zdravnikovimi navodili.
Patheon France 40 Boulevard de Champaret FR-38300 Bourgoin Jallieu France or 
Patheon France 40 Boulevard de Champaret FR-38300 Bourgoin Jallieu Francija ali
Keeping uric acid levels low by taking ADENURIC once every day stops crystals building up, and over time it reduces symptoms. 
Jemanje zdravila ADENURIC enkrat na dan ohranja nizko raven sečne kisline in prepreči nastanek kristalov, dolgoročno pa zmanjša simptome.
ADENURIC should be started two days before the beginning of cytotoxic therapy and continued for a minimum of 7 days; however treatment may be prolonged up to 9 days according to chemotherapy duration as per clinical judgment. 
Z zdravljenjem z zdravilom ADENURIC je potrebno začeti dva dni pred pričetkom terapije s citotoksičnimi kemoterapevtiki in nadaljevati z zdravilom ADENURIC za najmanj 7 dni; vendar se lahko zdravljenje podaljša do 9 dni odvisno od trajanja kemoterapije kot tudi klinične presoje.
5 How to store ADENURIC Contents of the pack and other information 
5 Shranjevanje zdravila ADENURIC Vsebina pakiranja in dodatne informacije
Overall, 346 patients with haematological malignancies undergoing chemotherapy and at intermediate / high risk of Tumor Lysis Syndrome were included. 
V celoti je bilo vključenih 346 bolnikov s hematološkim malignim obolenjem, pri katerih poteka zdravljenje s kemoterapijo in s srednje visokim/visokim tveganjem za nastanek sindroma tumorske lize.
Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. 
Febuksostat 80 mg se pri bolnikih, ki se sočasno zdravijo s teofilinom, lahko uporablja brez tveganja za povečanje plazemskih vrednosti teofilina.
In each phase 3 pivotal study, ADENURIC demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. 
V vsaki ključni študiji 3. faze je zdravilo ADENURIC dokazalo boljšo sposobnost zmanjšanja in vzdrževanja ravni sečne kisline v serumu v primerjavi z alopurinolom.
Excipient(s) with known effects: 
Pomožne snovi z znanim učinkom:
If you take more ADENURIC than you should 
Če ste vzeli večji odmerek zdravila ADENURIC, kot bi smeli
It is important to keep taking ADENURIC even if you have a flare, as ADENURIC is still working to lower uric acid. 
Pomembno je, da z jemanjem zdravila ADENURIC nadaljujete tudi, če pride do izbruha protina, saj zdravilo ADENURIC še vedno znižuje raven sečne kisline.
If you have been told that you have an intolerance to some sugars contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Thus, ADENURIC may be taken without regard to food. 
Zato se lahko zdravilo ADENURIC jemlje ne glede na hrano.
ADENURIC 120 mg tablets is also used to treat and prevent high blood levels of uric acid that may occur when you start to receive chemotherapy for blood cancers. 
Zdravilo ADENURIC 120 mg tablete uporabljamo tudi za zdravljenje in preprečevanje visokih ravni sečne kisline v krvi, ki se lahko pojavijo ob začetku zdravljenja krvnega raka s kemoterapijo.
ADENURIC is indicated in adults. 
Zdravilo ADENURIC je indicirano pri odraslih.
Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience 
Preglednica 1: Neželeni učinki v kombiniranih študijah 3. faze, dolgoročnih podaljšanih študijah in v obdobju trženja
Other medicines and ADENURIC 
Druga zdravila in zdravilo ADENURIC
This has not been observed in the pivotal clinical study with ADENURIC in the Tumor Lysis Syndrome. 
Tega v pilotski klinični študiji z zdravilom ADENURIC pri sindromu tumorske lize ni bilo opaženo.
Continue to take ADENURIC every day even when you are not experiencing gout flare or attack. 
Z jemanjem zdravila ADENURIC nadaljujte vsak dan, tudi ko pri vas ne pride do izbruha ali poslabšanja protina.
• hot flushes or flushing (e.g. redness of the face or neck), increased blood pressure, bleeding (hemorrhage, seen only in patients taking chemotherapy for blood disorders) 
• vročinski oblivi (npr. pordelost obraza ali vratu), zvišan krvni tlak, krvavitev (hemoragija, opažena samo pri bolnikih, zdravljenih s kemoterapijo zaradi bolezni krvi),
No data is available for febuxostat 120 mg. 
Na voljo ni podatkov za febuksostat 120 mg.
ADENURIC tablets contain lactose (a type of sugar). 
Zdravilo ADENURIC vsebuje laktozo (vrsto sladkorja).
It is unknown whether febuxostat is excreted in human breast milk. 
Ni znano, ali se pri ljudeh febuksostat izloča v materino mleko.
Film-coated tablet (tablets). 
FARMACEVTSKA OBLIKA filmsko obložena tableta (tableta)
If you stop taking ADENURIC your uric acid levels may begin to rise and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys. 
Če prenehate jemati zdravilo ADENURIC, se lahko ravni sečne kisline znova povišajo in pride do poslabšanja simptomov zaradi nastajanja novih kristalov urata v sklepih in ledvicah.
Each tablet contains 114.75 mg of lactose (as monohydrate) 
Ena tableta vsebuje 114,75 mg laktoze (v obliki monohidrata).
No dose adjustment is required in the elderly (see section 5.2). 
Starejši Pri starostnikih odmerka ni treba prilagajati (glejte poglavje 5.2).
Each tablet contains 76.50 mg of lactose (as monohydrate) 
Ena tableta vsebuje 76,50 mg laktoze (v obliki monohidrata).
ADENURIC 80 mg and 120 mg is packed in clear (Aclar/PVC/Aluminium or PVC/PE/PVDC/Aluminium) blister of 14 tablets. 
Zdravili ADENURIC 80 mg in 120 mg sta na voljo v prozornih (Aclar/PVC/aluminij ali PVC/PE/PVDC/aluminij) pretisnih omotih po 14 tablet.
Film-coating: Opadry II yellow, 85F42129 containing: polyvinyl alcohol, titanium dioxide (E171), macrogols 3350, talc, iron oxide yellow (E172) 
Filmska obloga: Opadry II rumena 85F42129, ki vsebuje: polivinil alkohol, titanov dioksid (E171), makrogol 3350, smukec, rumeni železov oksid (E172).
What ADENURIC is and what it is used for What you need to know before you take ADENURIC How to take ADENURIC 
Kaj je zdravilo ADENURIC in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo ADENURIC Kako jemati zdravilo ADENURIC Možni neželeni učinki
The primary endpoint in CARES was the time to first occurrence of MACE, a composite of non-fatal MI, non-fatal stroke, CV death and unstable angina with urgent coronary revascularization. 
Primarni opazovani dogodek študije CARES je bil čas do prvega pojava MACE, ki je sestavljen iz miokardnega infarkta (MI) brez smrtnega izida, možganske kapi brez smrtnega izida, smrti zaradi srčno-žilnega vzroka in nestabilne angine pektoris z nujno koronarno revaskularizacijo.
Patheon France 40 boulevard de Champaret 38300 Bourgoin Jallieu France or 
40 boulevard de Champaret 38300 Bourgoin Jallieu Francija ali
A. MANUFACTURE(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
If you miss a dose of ADENURIC take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time. 
Če pozabite vzeti odmerek zdravila ADENURIC, ga vzemite takoj, ko se spomnite, razen če je skoraj čas za naslednji odmerek.
In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with ADENURIC for Tumor Lysis Syndrome. 
Pri bolnikih, ki imajo zelo visoke vrednosti sečne kisline (npr. tisti, ki prejemajo kemoterapijo zaradi rakavega obolenja), lahko zdravila za zniževanje sečne kisline vodijo v odlaganje ksantina v sečilih, z možnimi kamni, čeprav tega ni bilo opaženo pri bolnikih, ki so se zdravili z zdravilom ADENURIC zaradi sindroma tumorske lize.
Clear (Aclar/PVC/Aluminium or PVC/PE/PVDC/Aluminium) blister of 14 tablets. 
Prozorni (Aclar/PVC/aluminij ali PVC/PE/PVDC/aluminij) pretisni omot s 14 tabletami.
It is not known if ADENURIC may pass into human breast milk. 
Ni znano, ali zdravilo ADENURIC prehaja v materino mleko.
INR and Factor VII activity were also not affected by the coadministration of febuxostat. 
Tudi INR in aktivnost faktorja VII se nista spremenili pri sočasnem dajanju febuksostata.
• nervousness 
• Živčnost,
• rash (including various types of rash, please see below under “uncommon” and “rare” sections) 
• izpuščaj (vključno z različnimi tipi izpuščajev, ki so našteti spodaj med »občasnimi« in
ADENURIC tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. 
Tablete ADENURIC vsebujejo zdravilno učinkovino febuksostat in jih uporabljamo za zdravljenje protina, ki je povezan z izločanjem substance, ki se imenuje sečna kislina (urati) v telesu.
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. 
Sečna kislina je končni produkt presnove purina pri ljudeh in nastaja v kaskadi hipoksantin  ksantin  sečna kislina.
The back of the blister pack is marked with the days of the week to help you check that you have taken a dose each day. 
• Običajni odmerek je ena tableta na dan. Na hrbtni strani pretisnega omota so oznake z dnevi v tednu, s pomočjo katerih lahko nadzirate vsakodnevno jemanje odmerka.
ADENURIC works by reducing uric acid levels. 
Zdravilo ADENURIC zmanjšuje ravni sečne kisline.
The 120 mg film-coated tablets are marked on one side with ‘120'. 
120 mg filmsko obložene tablete imajo na eni strani vtisnjeno oznako ‘120'.
ADENURIC is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS). 
Zdravilo ADENURIC je indicirano za preventivo in zdravljenje hiperurikemije pri odraslih bolnikih, pri katerih poteka zdravljenje hematološkega malignega obolenja s srednje visokim do visokim tveganjem nastanka sindroma tumorske lize (TLS - Tumor Lysis Syndrome) s kemoterapijo.
Do not stop taking ADENURIC without the advice of your doctor even if you feel better. 
Tudi če se počutite bolje, ne prenehajte jemati zdravila ADENURIC, razen če vam je to svetoval zdravnik.
Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience in gout patients. 
Preglednica 1: Neželeni učinki v kombiniranih študijah 3. faze, dolgoročne podaljšane študije in poročila v obdobju trženja pri bolnikih s protinom.
Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy 
Preventiva in zdravljenje visokih vrednosti sečne kisline pri bolnikih, ki zdravijo rakava obolenja s kemoterapijo
• Do not use this medicine after the expiry date which is stated on the carton and the tablet blister foil after ‘EXP.' 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49% and 38% decrease in Cmax and a 18% and 16% decrease in AUC, respectively. 
Pri ponavljajočih se peroralnih odmerkih 80 mg enkrat na dan ali enkratnem odmerku 120 mg z obrokom, bogatim z maščobami, se je vrednost Cmax znižala za 49 % oz. 38 %, AUC pa za 18 % oz. 16 %.
After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 µg/mL, and 5.0-5.3 µg/mL, respectively. 
Po enkratnem ali ponavljajočem se peroralnem odmerku 80 mg enkrat na dan je Cmax približno 2,8-3,2 µg/ml, pri odmerku 120 mg pa 5,05,3 µg/ml.
In the FLORENCE study ADENURIC demonstrated a superior control of serum uric acid level compared to allopurinol in patients scheduled to receive the latter drug. 
Vštudiji FLORENCE se je pri zdravilu ADENURIC pokazalo boljše uravnavanje vrednosti sečne kisline v primerjavi z alopurinolom pri bolnikih, ki so bili predvideni za prejem slednjega zdravila.
What you need to know before you take ADENURIC Do not take ADENURIC 
Kaj morate vedeti, preden boste vzeli zdravilo ADENURIC Ne jemljite zdravila ADENURIC:
What ADENURIC looks like and contents of the pack 
Izgled zdravila ADENURIC in vsebina pakiranja
An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to < 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied). 
Analiza pri bolnikih s protinom in okvaro ledvic je bila nato določena v študiji CONFIRMS in pokazala, da je bil febuksostat statistično pomembno učinkovitejši pri zmanjševanju serumskih ravni sečne kisline na < 6 mg/dl v primerjavi z alopurinolom 300 mg/200 mg pri bolnikih s protinom in blago do zmerno okvaro ledvic (65 % bolnikov).
• dizziness, numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia) 
• omotičnost, občutek odrevenelosti ali ščemenja, zmanjšano ali spremenjeno zaznavanje (hipestezija, hemipareza ali parestezija) sprememba čuta za okušanje, zmanjšanje občutka za vonj (hiposmija),
The proportion of patients with serum urate levels of <6.0 mg/dL (357 µmol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose. 
Delež bolnikov z vrednostmi uratov v serumu < 6,0 mg/dl (357 mol/l) je bil na zaključnem obisku večji kot 80 % (81-100 %) neodvisno od odmerka febuksostata.
Co-administration of febuxostat 80 mg and theophylline 400mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section 4.5). 
Ob sočasnem jemanju 80 mg febuksostata in 400 mg teofilina v enkratnem odmerku pri zdravih prostovoljcih ni bilo nikakršnih farmakokinetičnih interakcij (glejte poglavje 4.5).
In a study in healthy subjects, 120 mg ADENURIC QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. 
V študiji pri zdravih prostovoljcih, ki so jemali ADENURIC v odmerku 120 mg enkrat na dan, je prišlo do povprečno 22 % povečanja AUC dezipramina, substrata CYP2D6, kar kaže na potencialni šibek zaviralni učinek febuksostata na encim CYP2D6 in vivo.
If you forget to take ADENURIC 
Če ste pozabili vzeti zdravilo ADENURIC
If you stop taking ADENURIC 
Če ste prenehali jemati zdravilo ADENURIC